| Literature DB >> 34378959 |
Jeong Eun Lee1, Shinwon Lee1, Sohee Park1, Soon O Lee1, Sun H Lee1.
Abstract
Dysfunctional accessory gene regulator (agr) is associated with unfavorable outcomes in invasive methicillin-resistant Staphylococcus aureus infections. However, it is unknown whether this association persists in methicillin-susceptible Staphylococcus aureus bacteremia (MSSA-B). This study evaluated the association between agr dysfunction and mortality in patients with MSSA-B. This retrospective cohort study included MSSA-B patients (≥15 years) enrolled from June 2014 to June 2019 and retrospectively collected their demographic and clinical information. Stored causative strains were measured for agr functionality by δ-hemolysin production assays. Among 244 MSSA-B patients, 91 (37.3%) and 153 (62.7%) had dysfunctional and functional agr MSSA-B, respectively. Ninety-day mortality occurred in 18.7% and 17.6% dysfunctional and functional groups, respectively (P = 0.97). Kaplan-Meier analysis showed that mortality due to dysfunctional agr MSSA-B was not significantly higher (P = 0.82). Age, sites, the severity of infection, and comorbidity adjusted hazard ratio (aHR) of the dysfunctional group for 90-day mortality was 1.303 (95% confidence interval [CI], 0.698 to 2.436, P = 0.41). Mortality due to MSSA-B with sequential organ failure assessment (SOFA) scores of 2 to 5 was significantly higher in the dysfunctional group (P = 0.03), and the dysfunctional agr aHR for 90-day mortality was 3.260 (95% CI, 1.050 to 10.118, P = 0.04). The agr dysfunction of causative organisms can have a significant effect on the outcomes of MSSA-B in patients with moderate severity (SOFA scores 2 to 5). IMPORTANCE Few studies have examined the association between methicillin-susceptible Staphylococcus aureus (MSSA) infection and accessory gene regulator (agr) functionality. We evaluated the association between agr dysfunction and mortality in patients with MSSA bacteremia. Dysfunctional agr is associated with lower survival in MSSA bacteremia patients with moderately severe sequential organ failure assessment (SOFA) scores of 2 to 5. We found that the agr functionality of causative organisms may have an effect on patients' outcomes in MSSA like in methicillin-resistant S. aureus.Entities:
Keywords: MSSA; Staphylococcus aureus; agr; bacteremia; quorum sensing
Mesh:
Substances:
Year: 2021 PMID: 34378959 PMCID: PMC8552762 DOI: 10.1128/Spectrum.00116-21
Source DB: PubMed Journal: Microbiol Spectr ISSN: 2165-0497
Comparison of demographic, clinical, and microbiological characteristics according to the functionality of agr locus of MSSA bacteremia
| Characteristic | Value for group | ||
|---|---|---|---|
| Functional | Dysfunctional | ||
| Median age, yrs (IQR) | 65 (56–74) | 67.0 (56–74.5) | 0.447 |
| Older age (≥65 yrs) | 78 (51.0%) | 52 (57.1%) | 0.424 |
| Male | 106 (69.3%) | 62 (68.1%) | 0.964 |
| Community-onset | 92 (60.1%) | 56 (61.5%) | 0.934 |
| Comorbidity | |||
| Cardiovascular disease | 16 (10.5%) | 8 (8.8%) | 0.841 |
| Central nervous disease | 23 (15.0%) | 11 (12.1%) | 0.652 |
| Chronic lung disease | 2 (1.3%) | 1 (1.1%) | >0.999 |
| Chronic liver disease | 12 (7.8%) | 5 (5.5%) | 0.662 |
| Chronic kidney disease | 18 (11.8%) | 10 (11.0%) | >0.999 |
| Connective tissue disease | 3 (2.0%) | 2 (2.2%) | >0.999 |
| Solid organ malignancy | 22 (14.4%) | 14 (15.4%) | 0.978 |
| Hematologic malignancy | 17 (11.1%) | 5 (5.5%) | 0.211 |
| Diabetes mellitus | 42 (27.5%) | 25 (27.5%) | >0.999 |
| HIV infection | 1 (0.7%) | 0 (0.0%) | >0.999 |
| Median CCWI, score (IQR) | 4 (2–6) | 3 (2–5.5) | 0.883 |
| High CCWI (CCWI ≥ 3) | 102 (66.7%) | 61 (67.0%) | >0.999 |
| Site of infection | |||
| Unknown | 34 (22.2%) | 16 (17.6%) | 0.481 |
| Central line infections | 22 (14.4%) | 16 (17.6%) | 0.628 |
| Infective endocarditis | 5 (3.3%) | 4 (4.4%) | 0.920 |
| Osteomyelitis | 24 (15.7%) | 17 (18.7%) | 0.669 |
| Septic arthritis | 5 (3.3%) | 6 (6.6%) | 0.373 |
| Skin and soft tissue | 30 (19.6%) | 11 (12.1%) | 0.180 |
| Lung | 28 (18.3%) | 15 (16.5%) | 0.852 |
| Combined deep-seated abscesses | 26 (17.0%) | 21 (23.1%) | 0.319 |
| 0.001 | |||
| I | 106 (69.3%) | 54 (59.3%) | |
| II | 15 (9.8%) | 5 (5.5%) | |
| III | 19 (12.4%) | 29 (31.9%) | |
| IV | 13 (8.5%) | 3 (3.3%) | |
| 0.009 | |||
| A | 16 (10.5%) | 17 (18.7%) | |
| B | 40 (26.1%) | 34 (37.4%) | |
| C | 60 (39.2%) | 18 (19.8%) | |
| D | 4 (2.6%) | 5 (5.5%) | |
| None | 33 (21.6%) | 17 (18.7%) | |
| Cefazolin inoculum effect | 13 (8.5%) | 12 (13.2%) | 0.342 |
| Vancomycin MIC | 0.321 | ||
| <0.5 mg/liter | 76 (49.7%) | 42 (46.2%) | |
| 1 mg/liter | 74 (48.4%) | 49 (53.8%) | |
| 2 mg/liter | 3 (2.0%) | 0 (0.0%) | |
| SOFA score | 0.178 | ||
| 0–1 | 35 (22.9%) | 30 (33.0%) | |
| 2–5 | 77 (50.3%) | 43 (47.3%) | |
| ≥6 | 41 (26.8%) | 18 (19.8%) | |
| Appropriate empirical antibiotics | 150 (98.0%) | 91 (100%) | 0.457 |
| Definitive antibiotics | 0.925 | ||
| Nafcillin | 54 (35.3%) | 31 (34.1%) | |
| Cefazolin | 39 (25.5%) | 22 (24.2%) | |
| Others | 60 (39.2%) | 38 (41.8%) | |
| Outcomes | |||
| Median duration of bacteremia, day (IQR) | 1 (1–4) | 1 (1–3) | 0.267 |
| Persistent bacteremia | 22 (14.4%) | 9 (9.9%) | 0.413 |
| 7-D death | 10 (6.5%) | 8 (8.8%) | 0.690 |
| 30-D death | 22 (14.4%) | 14 (15.4%) | 0.978 |
| 90-D death | 27 (17.6%) | 17 (18.7%) | 0.975 |
agr, accessory gene regulator; MSSA, methicillin-susceptible Staphylococcus aureus; IQR, interquartile range; HIV, human immunodeficiency virus; CCWI, Charlson comorbidity weighted index; SOFA, sequential organ failure assessment; D, day.
Bivariate analysis of risk factors for 90-day mortality among patients with MSSA bacteremia
| Characteristic | Value for group | ||
|---|---|---|---|
| Survived ( | 90-day mortality ( | ||
| Median age, yrs (IQR) | 66 (54.5–74) | 68 (56.5–75.5) | 0.23 |
| Older age (≥65 yrs) | 105 (52.5%) | 25 (56.8%) | 0.72 |
| Male | 135 (67.5%) | 33 (75.0%) | 0.43 |
| Community onset | 129 (64.5%) | 19 (43.2%) | 0.01 |
| Comorbidity | |||
| Cardiovascular disease | 19 (9.5%) | 5 (11.4%) | 0.92 |
| Central nervous disease | 28 (14.0%) | 6 (13.6%) | >0.999 |
| Chronic lung disease | 3 (1.5%) | 0 (0.0%) | 0.95 |
| Chronic liver disease | 11 (5.5%) | 6 (13.6%) | 0.11 |
| Chronic kidney disease | 23 (11.5%) | 5 (11.4%) | >0.999 |
| Connective tissue disease | 3 (1.5%) | 2 (4.5%) | 0.48 |
| Solid organ malignancy | 26 (13.0%) | 10 (22.7%) | 0.16 |
| Hematologic malignancy | 16 (8.0%) | 6 (13.6%) | 0.37 |
| Diabetes mellitus | 56 (28.0%) | 11 (25.0%) | 0.83 |
| HIV infection | 1 (0.5%) | 0 (0.0%) | >0.999 |
| Median CCWI, score (IQR) | 3 (2–5) | 4 (3–7) | 0.003 |
| High CCWI (CCWI ≥ 3) | 124 (62.0%) | 39 (88.6%) | 0.001 |
| Site of infection | |||
| Unknown | 37 (18.5%) | 13 (29.5%) | 0.15 |
| Central line infections | 33 (16.5%) | 5 (11.4%) | 0.53 |
| Infective endocarditis | 5 (2.5%) | 4 (9.1%) | 0.10 |
| Osteomyelitis | 37 (18.5%) | 4 (9.1%) | 0.20 |
| Septic arthritis | 9 (4.5%) | 2 (4.5%) | >0.999 |
| Skin and soft tissue infection | 38 (19.0%) | 3 (6.8%) | 0.08 |
| Pneumonia | 29 (14.5%) | 14 (31.8%) | 0.01 |
| Combined deep-seated abscesses | 40 (20.0%) | 7 (15.9%) | 0.68 |
| 0.43 | |||
| I | 129 (64.5%) | 31 (70.5%) | |
| II | 15 (7.5%) | 5 (11.4%) | |
| III | 43 (21.5%) | 5 (11.4%) | |
| IV | 13 (6.5%) | 3 (6.8%) | |
| Dysfunctional | 74 (37.0%) | 17 (38.6%) | 0.97 |
| 0.664 | |||
| A | 29 (14.5%) | 4 (9.1%) | |
| B | 57 (28.5%) | 17 (38.6%) | |
| C | 65 (32.5%) | 13 (29.5%) | |
| D | 8 (4.0%) | 1 (2.3%) | |
| None | 41 (20.5%) | 9 (20.5%) | |
| Cefazolin inoculum effect | 22 (11.0%) | 3 (6.8%) | 0.58 |
| Vancomycin MIC | 0.626 | ||
| <0.5 mg/liter | 98 (49.0%) | 20 (45.5%) | |
| 1 mg/liter | 99 (49.5%) | 24 (54.5%) | |
| 2 mg/liter | 3 (1.5%) | 0 (0.0%) | |
| SOFA score | <0.001 | ||
| 0–1 | 64 (32.0%) | 1 (2.3%) | |
| 2–5 | 105 (52.5%) | 15 (34.1%) | |
| ≥6 | 31 (15.5%) | 28 (63.6%) | |
| Appropriate empirical antibiotics | 197 (98.5%) | 44 (100.0%) | 0.95 |
| Definitive antibiotics | 0.04 | ||
| Nafcillin | 73 (36.5%) | 12 (27.3%) | |
| Cefazolin | 54 (27.0%) | 7 (15.9%) | |
| Others | 73 (36.5%) | 25 (56.8%) | |
MSSA, methicillin-susceptible Staphylococcus aureus; IQR, interquartile range; HIV, human immunodeficiency virus; CCWI, Charlson comorbidity weighted index; agr, accessory gene regulator; SOFA, sequential organ failure assessment.
Multivariate logistic regression analysis of risk factors for 90-day mortality among patients with MSSA bacteremia
| Characteristic | aOR (95% CI) | |
|---|---|---|
| Dysfunctional | 1.558 (0.669–3.653) | 0.30 |
| Cefazolin inoculum effect | 0.802 (0.141–3.402) | 0.78 |
| Community-onset bacteremia | 0.366 (0.147–0.870) | 0.03 |
| High CCWI (CCWI ≥ 3) | 6.260 (1.807–25.156) | 0.006 |
| SOFA score | ||
| 0–1 | 1 | |
| 2–5 | 8.0055 (1.453–150.494) | 0.05 |
| ≥6 | 52.276 (8.943–1,013.780) | <0.001 |
| Infective endocarditis | 8.131 (1.260–56.753) | 0.03 |
| Definitive antibiotics | ||
| Nafcillin | 1 | |
| Cefazolin | 0.929 (0.242–3.395) | 0.91 |
| Others | 1.443 (0.462–4.780) | 0.44 |
MSSA, methicillin-susceptible Staphylococcus aureus; aOR, adjusted odds ratio; CI, confidence interval; agr, accessory gene regulator; CCWI, Charlson comorbidity weighted index; SOFA, sequential organ failure assessment.
Mortality due to MSSA bacteremia stratified by the initial severity of infections between functional and dysfunctional agr groups
| Mortality rate for group | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SOFA 0–1 | SOFA 2–5 | SOFA ≥6 | |||||||
| Time of mortality (day) | Fx | DysFx | Fx | DysFx | Fx | DysFx | |||
| 7 | 0 (0%) | 0 (0%) | 0 (0%) | 4 (9.3%) | 0.03 | 10 (24.4%) | 4 (22.2%) | >0.999 | |
| 30 | 0 (0%) | 0 (0%) | 5 (6.5%) | 7 (16.3%) | 0.16 | 17 (41.5%) | 7 (38.9%) | >0.999 | |
| 90 | 1 (2.9%) | 0 (0%) | >0.999 | 6 (7.8%) | 9 (20.9%) | 0.07 | 20 (48.8%) | 8 (44.4%) | 0.98 |
MSSA, methicillin-susceptible Staphylococcus aureus; SOFA, sequential organ failure assessment; Fx agr, functional accessory gene regulator; DysFx agr, dysfunctional accessory gene regulator; D, day.
FIG 1Kaplan-Meier survival curve for 90-day mortality of MSSA-B with dysfunctional agr group or functional agr group according to the SOFA score overall (A), SOFA scores of 0 to 1 (B), SOFA score of 2 to 5 (C), SOFA scores of ≥6 (D).